SCHEMBL4052037

SCHEMBL4052037

CCOC(=O)CCc1cccc(-n2nc(C)cc2NC(=O)Nc2ccc(Cl)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.59
MAPT P10636 3/20 0.54
DDR2 Q16832 3/20 0.53
MAPK9 P45984 1/20 0.53
KCNJ6 P48051 3/20 0.53
KCNJ3 P48549 3/20 0.53
KCNJ5 P48544 2/20 0.53
TSHR P16473 1/20 0.53
NPSR1 Q6W5P4 2/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
SRC P12931 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
ALPG P10696 1/20 0.49
MAPK13 O15264 1/20 0.48
MAPK12 P53778 1/20 0.48
MAPK11 Q15759 1/20 0.48
NTRK1 P04629 1/20 0.48
BRAF P15056 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4048881 0.90 MAPK14 (0.56) MAPK14DDR2MAPK9KCNJ6KCNJ3
SCHEMBL3295232 0.90 MAPK14 (0.75) MAPK14DDR2MAPK9SRCMAPK13
SCHEMBL4055743 0.89 MAPK14 (0.64) MAPK14DDR2MAPK9KCNJ6KCNJ3
SCHEMBL4049398 0.89 PTPN1 (0.60) MAPK14MAPTDDR2MAPK9KCNJ6
SCHEMBL16317159 0.88 MAPK14 (0.54) MAPK14MAPTDDR2MAPK9KCNJ6
SCHEMBL3293954 0.81 MAPK14 (0.62) MAPK14DDR2MAPK9SRCMAPK13
SCHEMBL2081795 0.80 MAPK14 (0.79) MAPK14DDR2MAPK9SRCMAPK13
SCHEMBL3293295 0.80 MAPK14 (0.63) MAPK14DDR2MAPK9SRCMAPK13
SCHEMBL5189629 0.80 KCNJ6 (0.49) MAPK14MAPTKCNJ6KCNJ3KCNJ5
SCHEMBL3296144 0.79 MAPK14 (0.70) MAPK14MAPTDDR2MAPK9SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
EP-1836173-A4 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2009-07-08 EP disclosed
EP-1836173-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 EP disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 MAPK14 80/4885MAPT 2609/4885DDR2 888/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MAPK14 29/4885MAPT 1430/4885DDR2 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.